Akash Tewari, an analyst from Jefferies, maintained the Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report). The associated price target remains the same with $183.00.
Akash Tewari has given his Buy rating due to a combination of factors that suggest Jazz Pharmaceuticals is undervalued despite recent market reactions. The stock has declined approximately 12% following discussions of potential tariffs on Irish drug imports, but Tewari believes this reaction is excessive.
Even under aggressive scenarios, such as a 200% tariff and a 21% tax rate, the discounted cash flow valuation for Jazz Pharmaceuticals remains significantly higher than the current stock price, indicating potential for growth. Additionally, Tewari is optimistic about the company’s future prospects, particularly with the anticipated success of Zani in the GEA market, which could generate over $1 billion in revenue. Overall, the potential tariff impact appears minimal, and the company’s strategic positioning and product pipeline support a Buy recommendation.
In another report released on March 19, Bank of America Securities also reiterated a Buy rating on the stock with a $213.00 price target.